# Nautilus Biotechnology to Participate in Upcoming September Investor Conferences
Canonical URL: https://biopharmsignal.com/news/NAUT/nautilus-biotechnology-to-participate-in-upcoming-september-investor-conferences-8ef6522e
Ticker: NAUT
Company: Nautilus Biotechnology
Source: Nautilus Biotechnology
Published: 2025-08-27 12:00 EST
## Summary

Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein...

## Article Body
Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the following investor conferences.

Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY Management is scheduled to participate in a fireside chat on Monday, September 8 h at 10:50 a.m. Pacific Time / 1:50 p.m. Eastern Time.

Q3 Investor Summit Group Virtual Conference Management is scheduled to present on Tuesday, September 16 th at 10:00 a.m. Pacific Time / 1:00 p.m. Eastern Time and will host 1x1 meetings on Wednesday, September 17 th .

Interested parties may access live and archived webcasts of the presentations on the “Investors” section of the company website at: www.nautilus.bio .

About Nautilus Biotechnology, Inc. With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio .

Media Contact press@nautilus.bio

Investor Contact investorrelations@nautilus.bio
## Recent Company News
- 2026-07-28 12:00 EST — [Nautilus Biotechnology Reports Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/NAUT/nautilus-biotechnology-reports-second-quarter-2026-financial-results-6bb2d24b) — Source: Nautilus Biotechnology
- 2026-07-08 12:00 EST — [Nautilus Biotechnology to Announce Second Quarter 2026  Financial Results on July 28, 2026](https://biopharmsignal.com/news/NAUT/nautilus-biotechnology-to-announce-second-quarter-2026-financial-results-on-july-ffc9b6aa) — Source: Nautilus Biotechnology
- 2026-04-28 12:00 EST — [Nautilus Biotechnology Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/NAUT/nautilus-biotechnology-reports-first-quarter-2026-financial-results-be1ada7a) — Source: Nautilus Biotechnology
- 2026-04-09 12:00 EST — [Nautilus Biotechnology to Announce First Quarter 2026 Financial Results on April 28, 2026](https://biopharmsignal.com/news/NAUT/nautilus-biotechnology-to-announce-first-quarter-2026-financial-results-on-april-a00320ac) — Source: Nautilus Biotechnology
- 2026-03-24 12:00 EST — [Nautilus Biotechnology to Participate in the Investor Summit Group Virtual Conference](https://biopharmsignal.com/news/NAUT/nautilus-biotechnology-to-participate-in-the-investor-summit-group-virtual-confe-1d3fd49b) — Source: Nautilus Biotechnology
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)